Home | Welcome to Contract Pharma   
Last Updated Wednesday, August 27 2014
Print RSS Feed

Financial Report: Covance



Published January 25, 2013
Related Searches: Development Toxicology
Covance
 
4Q Revenues: $562 million (+5%)

4Q Earnings: $33.9 million (+60%)

YTD Revenues: $2.2 billion (+6%)

YTD Earnings: $94.7 million (-28%)

Comments: Late-Stage Development revenues in the quarter grew 16% to $345 million, led by 22% growth in clinical development and 16% growth in central labs, which offset a decline in market access services. For the year Late-Stage Development revenues grew 13% to $1.3 billion. Early Development revenues were down 7% to $217.4 million in the quarter and $869.5 million for the year, due to declines in toxicology, discovery support, and clinical pharmacology, the impact of the sale of environmental services, and the closure of sites in 2012. Restructuring costs were $6.6 million in the quarter and $73.1 million for the year.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On